AMG National Trust Bank Has $4.41 Million Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

AMG National Trust Bank raised its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 11.2% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 39,000 shares of the medical equipment provider's stock after buying an additional 3,921 shares during the period. AMG National Trust Bank's holdings in Zimmer Biomet were worth $4,414,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of ZBH. MGO One Seven LLC lifted its stake in Zimmer Biomet by 5.1% in the fourth quarter. MGO One Seven LLC now owns 2,254 shares of the medical equipment provider's stock worth $238,000 after purchasing an additional 110 shares during the last quarter. Janney Montgomery Scott LLC raised its position in shares of Zimmer Biomet by 0.5% in the 1st quarter. Janney Montgomery Scott LLC now owns 25,647 shares of the medical equipment provider's stock worth $2,903,000 after acquiring an additional 118 shares in the last quarter. Curbstone Financial Management Corp boosted its holdings in shares of Zimmer Biomet by 3.4% in the 1st quarter. Curbstone Financial Management Corp now owns 4,266 shares of the medical equipment provider's stock valued at $483,000 after buying an additional 140 shares in the last quarter. Roberts Wealth Advisors LLC grew its holdings in Zimmer Biomet by 0.8% in the first quarter. Roberts Wealth Advisors LLC now owns 18,497 shares of the medical equipment provider's stock worth $2,093,000 after purchasing an additional 152 shares during the last quarter. Finally, Hazlett Burt & Watson Inc. grew its stake in Zimmer Biomet by 23.7% during the 4th quarter. Hazlett Burt & Watson Inc. now owns 815 shares of the medical equipment provider's stock worth $85,000 after buying an additional 156 shares during the last quarter. Institutional investors own 88.89% of the company's stock.

Insider Activity

In related news, insider Sang Yi sold 1,000 shares of the firm's stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total transaction of $95,000.00. Following the transaction, the insider directly owned 20,424 shares in the company, valued at $1,940,280. This trade represents a 4.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 1.39% of the company's stock.

Analyst Ratings Changes

ZBH has been the topic of several recent research reports. Morgan Stanley lowered their price objective on Zimmer Biomet from $115.00 to $95.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. JMP Securities dropped their price target on shares of Zimmer Biomet from $140.00 to $125.00 and set a "market outperform" rating for the company in a research note on Wednesday, May 7th. Evercore ISI reduced their price objective on shares of Zimmer Biomet from $102.00 to $96.00 and set an "in-line" rating on the stock in a report on Tuesday, July 8th. Stifel Nicolaus set a $115.00 target price on Zimmer Biomet and gave the company a "buy" rating in a research report on Tuesday, May 6th. Finally, Wells Fargo & Company reduced their price target on Zimmer Biomet from $113.00 to $98.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $111.39.

Zimmer Biomet Price Performance

Zimmer Biomet stock traded down $1.72 during mid-day trading on Friday, hitting $93.18. 1,314,882 shares of the company were exchanged, compared to its average volume of 1,830,353. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.44 and a quick ratio of 1.46. The business's 50 day simple moving average is $93.26 and its two-hundred day simple moving average is $100.92. The company has a market capitalization of $18.44 billion, a P/E ratio of 20.62, a PEG ratio of 2.15 and a beta of 0.71. Zimmer Biomet Holdings, Inc. has a 12-month low of $89.22 and a 12-month high of $116.71.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. The business had revenue of $1.91 billion during the quarter, compared to the consensus estimate of $1.89 billion. Zimmer Biomet had a return on equity of 12.73% and a net margin of 11.86%. The business's revenue for the quarter was up 1.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.94 earnings per share. Analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Thursday, June 26th will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.03%. The ex-dividend date is Thursday, June 26th. Zimmer Biomet's payout ratio is 21.24%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.